Provigil Tapering Guide
modafinil
Overview
Modafinil is a wakefulness-promoting agent (eugeroic) approved for narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It is widely prescribed off-label for fatigue, ADHD, and cognitive enhancement.
100mg, 200mg
Tablets: 100mg, 200mg
Avoid in pregnancy — recent data suggest increased risk of congenital malformations
Mechanism of Action
Mechanism is not fully understood. Modafinil weakly inhibits the dopamine transporter (DAT), increasing extracellular dopamine. It also affects orexin/hypocretin, histamine, norepinephrine, serotonin, and GABA systems involved in wakefulness regulation.
Taper Notes
Modafinil has low classical dependence potential, but psychological reliance and rebound fatigue/sleepiness on discontinuation are common. A 2-4 week stepdown helps with rebound symptoms.
Hyperbolic Tapering Guidance
Modafinil is not classically habit-forming, but stopping abruptly often unmasks the underlying sleep disorder. Stepwise reductions over 2-4 weeks (e.g., 200 → 100 → 50mg) plus addressing the underlying condition (CPAP for OSA, sleep schedule for shift work) reduce rebound severity.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reduction | 1-2 weeks | Reduce from 200mg to 100mg daily. Most users tolerate this step well. |
| Middle reduction | 1-2 weeks | Reduce to 50mg (half-tablet) or alternate-day dosing. |
| Final discontinuation | 1-2 weeks | Discontinue. Consider lifestyle/sleep-hygiene support and address underlying conditions. |
Withdrawal Timeline
1-2 days after dose reduction
3-7 days
Typically within 1-2 weeks for most symptoms
Rebound fatigue and low mood may persist 2-4 weeks; underlying sleep disorders re-emerge if unaddressed
Community Tips
Practical insights shared by members tapering Provigil. Not medical advice — always consult your prescriber.
- 1Plan your taper around a low-demand period — rebound fatigue is real even when classical withdrawal is not.
- 2If you were using modafinil to compensate for a sleep disorder (OSA, narcolepsy), make sure that condition is being treated independently before discontinuing.
- 3Hydration, light exposure in the morning, and a strict sleep schedule blunt the worst of the rebound.
- 4If you are on hormonal contraception, remember that contraceptive efficacy returns to normal only after a month off modafinil — use backup until then.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Hormonal contraceptives — modafinil induces CYP3A4 and reduces contraceptive efficacy; use additional contraception during and for 1 month after
- Cyclosporine and other CYP3A4 substrates — reduced exposure
- Warfarin — monitor INR (modafinil affects CYP2C9)
Food Interactions
- Food delays Tmax by ~1 hour but does not affect total exposure
- Avoid combining with high doses of caffeine or other stimulants
Contraindications
- Known hypersensitivity to modafinil or armodafinil
- History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant-related symptoms
Toxicity
Severe rash including Stevens-Johnson syndrome (rare). Cardiovascular effects (tachycardia, hypertension). Psychiatric effects including mania, psychosis, and suicidal ideation.
Pharmacokinetics
ADME Profile
Rapidly absorbed, Tmax 2–4 hours. Food may delay absorption but does not affect overall bioavailability.
~0.9 L/kg
Hepatic metabolism, primarily via amide hydrolysis and CYP3A4 to inactive metabolites (modafinil acid, modafinil sulfone).
Renal (~80% as metabolites), <10% unchanged.
~60% (primarily albumin)
~50 mL/min
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Provigil (modafinil) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Wilens TE, Adler LA, Adams J, et al. 2008 — Misuse and diversion of stimulants prescribed for ADHD (Journal of the American Academy of Child & Adolescent Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Clinician-facing deprescribing algorithms
- Royal College of Psychiatrists — ADHD resources — UK clinical guidance on adult ADHD pharmacotherapy
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Mad in America — stimulant coverage — Independent journalism on stimulant prescribing and discontinuation
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- Surviving Antidepressants — other medications forum — Community discussion of stimulant taper experiences
- RxISK — adverse drug reaction reporting — Independent database of stimulant adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.